Page last updated: 2024-12-11
flazin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
flazin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5377686 |
| CHEMBL ID | 1822160 |
| CHEBI ID | 69443 |
| SCHEMBL ID | 18939677 |
| MeSH ID | M0156836 |
Synonyms (23)
| Synonym |
|---|
| flazin |
| inchi=1/c17h12n2o4/c20-8-9-5-6-14(23-9)16-15-11(7-13(19-16)17(21)22)10-3-1-2-4-12(10)18-15/h1-7,18,20h,8h2,(h,21,22) |
| usbwyuykhhillz-uhfffaoysa- |
| 1-[5-(hydroxymethyl)-2-furyl]-9h-pyrido[3,4-b]indole-3-carboxylic acid |
| 9h-pyrido[3,4-b]indole-3-carboxylic acid, 1-[5-(hydroxymethyl)-2-furanyl]- |
| CHEMBL1822160 |
| flazine |
| chebi:69443 , |
| 1-[5-(hydroxymethyl)furan-2-yl]-9h-pyrido[3,4-b]indole-3-carboxylic acid |
| 9h-pyrido(3,4-b)indole-3-carboxylic acid, 1-(5-(hydroxymethyl)-2-furanyl)- |
| 100041-05-2 |
| USBWYUYKHHILLZ-UHFFFAOYSA-N |
| 1-[5-(hydroxymethyl)-2-furyl]-9h-beta-carboline-3-carboxylic acid # |
| DTXSID20142890 |
| SCHEMBL18939677 |
| HY-141508 |
| 1-[5-(hydroxymethyl)-2-furanyl]-9h-pyrido[3,4-b]indole-3-carboxylic acid, 9ci |
| Q27137781 |
| 1-(5-(hydroxymethyl)furan-2-yl)-9h-pyrido[3,4-b]indole-3-carboxylic acid |
| EX-A5451 |
| CS-0173663 |
| AKOS040763155 |
| F92711 |
Research Excerpts
Overview
Flazin is a diet-derived bioactive constituent mainly existing in fermented foods. The lipid metabolism improvement function of Flazin has not been studied.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Flazin is a diet-derived bioactive constituent mainly existing in fermented foods, of which the lipid metabolism improvement function has not been studied." | ( Flazin as a Lipid Droplet Regulator against Lipid Disorders. Chen, Y; Chen, Z; Chiba, H; Hui, SP; Jia, J; Shen, N; Wu, X; Wu, Y, 2022) | 2.89 |
| "Flazin is a β-carboline-derived alkaloid found in Japanese fermented foods. " | ( Flazin as a Promising Nrf2 Pathway Activator. Chiba, H; Fuda, H; Furukawa, T; Hui, SP; Joko, S; Miyanaga, S; Roan, Y; Suzuki, H; Umetsu, S; Watanabe, M, 2019) | 3.4 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " According to ADME (absorption, distribution, metabolism, and excretion) simulation in silico, flazin had good oral bioavailability in vivo." | ( Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor. Li, H; Lin, L; Su, G; Wang, Y; Zhao, M, 2016) | 0.87 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| harmala alkaloid | Any member of a class of naturally occurring alkaloids based on a 1-methyl-9H-beta-carboline skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1378314 | Therapeutic Index, ratio of CC50 for human C8166 cells to EC50 for HIV1 3B infected in human C8166 cells | 2017 | Journal of natural products, 07-28, Volume: 80, Issue:7 | Mushroom-Derived Indole Alkaloids. |
| AID1191968 | Antiviral activity against HIV | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity. |
| AID616383 | Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release | 2011 | Journal of natural products, Sep-23, Volume: 74, Issue:9 | Anti-inflammatory principles from Cordyceps sinensis. |
| AID616299 | Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation | 2011 | Journal of natural products, Sep-23, Volume: 74, Issue:9 | Anti-inflammatory principles from Cordyceps sinensis. |
| AID1378313 | Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of virus-induced syncytia formation after 3 days | 2017 | Journal of natural products, 07-28, Volume: 80, Issue:7 | Mushroom-Derived Indole Alkaloids. |
| AID616386 | Antioxidant activity assessed DPPH scavenging activity at 500 uM | 2011 | Journal of natural products, Sep-23, Volume: 74, Issue:9 | Anti-inflammatory principles from Cordyceps sinensis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 70.27
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (70.27) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||